Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study

Background: The SAKK 17/16 study showed promising efficacy data with lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma. Here, we evaluated long-term outcome and analyzed the impact of lurbinectedin monotherapy on the tumor microenvironment at the cellular an...

Full description

Bibliographic Details
Main Authors: Benedetti, F. (Author), Ceresoli, G.L (Author), Dagher, J. (Author), Froesch, P. (Author), Früh, M. (Author), Grosso, F. (Author), Hayoz, S. (Author), Kandalaft, L. (Author), Maconi, A. (Author), Mark, M. (Author), Metaxas, Y. (Author), Pless, M. (Author), Rusakiewicz, S. (Author), Schmid, S. (Author), Schneider, M. (Author), Tarussio, D. (Author), Tissot-Renaud, S. (Author), von Moos, R. (Author), Zucali, P. (Author)
Format: Article
Language:English
Published: Elsevier B.V. 2022
Subjects:
lurbinectedin
M2 phenotype
malignant pleural mesothelioma
regulatory T cells
tumor-associated macrophages
tumor-infiltrating lymphocytes
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items